Navigation Links
Bentley Reports Positive Results with Nasulin Intranasal Insulin,Spray at the American Diabetes Association Meeting

EXETER, N.H.--(BUSINESS WIRE)--Jun 25, 2007 - Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, today announced positive clinical results in three Company-sponsored studies of its investigational drug, Nasulin(TM), an intranasal insulin spray. The data were presented this past weekend at the American Diabetes Association 67th Scientific Sessions in Chicago.

In a placebo-controlled Phase II pharmacokinetic study in patients with type 1 diabetes, the 12 patients receiving Nasulin demonstrated more rapid onset of action than when they received either regular or fast-acting injectable insulins. In addition, blood sugar levels for two hours after eating in patients treated with Nasulin were similar to those who received both injectable insulin formulations. No adverse events were reported during this study.

Patients in the study were randomized to receive the following 4 regimens: intranasal doses of 25 IU Nasulin (approximately bioequivalent to 5 IU insulin SC), regular insulin (Humulin R(R) (5 IU)), rapid-acting insulin (Humalog(R) (5 IU)) and saline nasal spray (placebo). The primary objectives of the trial were to compare the pharmacokinetic and glucodynamic characteristics of Nasulin, as well as its bioavailability/bioequivalency, with injectable forms of insulin. Each regimen was given after an overnight insulin drip to maintain standard glucose levels. Each patient received a 450 calorie high-protein boost challenge after the study drug was administered.

Researchers also presented results from two additional Bentley-sponsored studies to determine if smoking had any effect on the absorption of Nasulin in normal male smokers and non-smokers and to determine if there were any absorption differences due to the normal nasal cycles that occur between nostrils (alternating levels of mild congestion). Nasulin was absorbed equally in a study of 18 smokers and 18 non-smokers,
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
(Date:7/28/2014)... , July 28, 2014  Serco Inc., a ... the Company has been awarded a re-compete contract ... (NEMSCOM) and its Deployable Medical Systems.  Serco will ... personnel to provide world-class healthcare to meet warfighter ... across the globe. The five year contract has ...
(Date:7/28/2014)... , July 28, 2014  Array BioPharma Inc. ... for the fourth quarter and full year ... call to discuss those results on Tuesday, ... Officer and Michael Carruthers , Chief ... InformationDate:Tuesday, August 12, 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) ...
(Date:7/28/2014)... HONG KONG , July 28, 2014  Syneron ... global aesthetic device company, announced today that its new ... tattoos of all types and colors and pigmented lesions ... innovative dual wavelength device, with 532nm and 1064nm wavelengths, ... to the skin using pulses which are trillionths of ...
Breaking Medicine Technology:Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4
... As previously announced, primary endpoint not met; ... with ERBITUX,-, NEW YORK, April 16, 2007 ... Company today,announced detailed results from the EPIC ... trial - comparing ERBITUX(R),(Cetuximab) plus irinotecan to ...
... WIRE)--Apr 17, 2007 - Curis, Inc.,(NASDAQ:CRIS), a ... primarily for cancer treatment, today announced that ... the 98th Annual Meeting,of the American Association ... also disclosed that its April 2005 discovery,collaboration ...
Cached Medicine Technology:Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 2Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 3Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 4
(Date:7/28/2014)... 28, 2014 (HealthDay News) -- British researchers report that ... fewer germs around. In their experiments, the scientists ... germs from one person to the other than what ... more casual exchange might suffice as a cultural substitute ... are published in the August issue of the ...
(Date:7/28/2014)... July 28, 2014 Parker Waichman LLP, a ... to ensure that the heroes of 9/11 are never forgotten, ... announced an important deadline. According to a VCF message ... a covered cancer on or before October 12, 2012 must ... First responders and others who were allegedly injured by the ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July ... relieve sleep apnea in children, but a new study confirms ... if they,re already overweight. The researchers said that,s a ... of health problems -- including, ironically, sleep apnea. But they,re ... Instead, they said, doctors and parents should be aware that ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Sarasota-based FCCI ... Best Companies To Work For. Still headquartered in Sarasota ... the only Florida-domiciled company in the top ten of ... Companies list appears in the August issue of Florida ... and large employer categories. Ranked #7 for 2014, FCCI ...
(Date:7/28/2014)... improving treatment for patients with one of the UK,s ... boost. , Chronic obstructive pulmonary disease (COPD) is the ... difficulties due to long-term damage to the lungs. ... per cent of all hospital admissions in the UK, ... hospital after they are discharged. , A ...
Breaking Medicine News(10 mins):Health News:'Fist Bump' May Beat Handshake for Cleanliness 2Health News:'Fist Bump' May Beat Handshake for Cleanliness 3Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 2Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 3Health News:FCCI Insurance Group Makes Top 100 Best Companies List – and is the Only Florida-Headquartered Company in Top Ten 2Health News:FCCI Insurance Group Makes Top 100 Best Companies List – and is the Only Florida-Headquartered Company in Top Ten 3Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3
... termed ripples and fast ripples, recorded by intracranial ... the localization of the brain region responsible for ... in Epilepsia , a journal of the ... brain regions containing fast ripples, along with the ...
... clinical associate professor of psychiatry and director of the ... School of Medicine (BUSM), has been selected as the ... Training by the Association of Psychology Postdoctoral and Internship ... during the American Psychological Association,s Convention in Washington, DC, ...
... HealthDay Reporter , THURSDAY, July 28 (HealthDay News) -- The ... -- pregnancy has increased dramatically in recent years, according to ... the rate of pregnancy-related stroke hospitalizations went up by 54 ... see some increase in pregnancy-related stroke, but we did not ...
... , THURSDAY, July 28 (HealthDay News) -- Children ... of developing blood cancers -- such as leukemia, multiple ... new study contends. The researchers pointed out that ... and effect can be established, but they suggested that ...
... University of North Carolina-led international study shows that among ... of human papillomavirus-associated precancerous lesions of the penis. Human ... that plays an important role in genital cancers in ... cervix. Jennifer Smith, PhD, senior author, says, "Our ...
... July 28 (HealthDay News) -- Increasing your muscle mass can ... study suggests. Researchers analyzed data from 13,644 adults who ... Survey III between 1988 and 1994. They found that for ... -- the ratio of muscle mass to total body weight ...
Cached Medicine News:Health News:Fast ripples confirmed to be valuable biomarker of area responsible for seizure activity in children 2Health News:Pregnancy-Related Strokes Jump 54 Percent 2Health News:Pregnancy-Related Strokes Jump 54 Percent 3Health News:Growing Up Near Livestock Tied to Blood Cancers 2Health News:Male circumcision lowers prevalence of penile precancerous lesions among African men 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: